Publications by authors named "Michael Tanen"

Claim this Profile
E
Evaluation of Urinary Renal Biomarkers for Early Prediction of Acute Kidney Injury Following Partial Nephrectomy: A Feasibility Study.
Brian R Lane, Stephen K Babitz, Katerina Vlasakova, Allen Wong, Sabrina L Noyes, Michael Tanen

Eur Urol Focus· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
K Chris Min, Marissa F Dockendorf, John Palcza, Jack Tseng, Lei Ma, Michael Tanen

Clin Pharmacol Ther· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.
Yi Mo, Julie Stromswold, Kimberly Wilson, Daniel Holder, Cyrille Sur, Michael Tanen

Alzheimers Dement (Amst)· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
Matthew E Kennedy, Andrew W Stamford, Xia Chen, Kathleen Cox, Jared N Cumming, Michael Tanen

Sci Transl Med· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of TH2 biomarkers in sputum of asthmatics following inhaled allergen.
Rob G J A Zuiker, Marcella K Ruddy, Nicoletta Morelli, Robin Mogg, Veronica M Rivas, Michael R L Tanen

Eur Clin Respir J· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Jeffrey L Seeburger, Daniel J Holder, Marc Combrinck, Catharine Joachim, Omar Laterza, Michael Tanen

J Alzheimers Dis· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next generation ligand binding assays-review of emerging real-time measurement technologies.
Stephanie Fraser, Mark Cameron, Edward O'Connor, Martin Schwickart, Michael Tanen

AAPS J· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry.
Thomas McAvoy, Michael E Lassman, Daniel S Spellman, Zhenlian Ke, Bonnie J Howell, Michael Tanen

Clin Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput simultaneous analysis of RNA, protein, and lipid biomarkers in heterogeneous tissue samples.
Vladimír Reiser, Ryan C Smith, Jiyan Xue, Marc M Kurtz, Rong Liu, Michael R Tanen

Clin Chem· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20.
Arnaldo M Pica-Mendez, Michael Tanen, Aimee Dallob, Wesley Tanaka, Omar F Laterza

Clin Chim Acta· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Gary A Herman, Arthur Bergman, Catherine Stevens, Paul Kotey, Bingming Yi, Michael Tanen

J Clin Endocrinol Metab· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
Gary A Herman, Arthur Bergman, Fang Liu, Cathy Stevens, Amy Q Wang, Michael Tanen

J Clin Pharmacol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Arthur J Bergman, Catherine Stevens, YanYan Zhou, Bingming Yi, Martine Laethem, Michael Tanen

Clin Ther· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Gary A Herman, Cathy Stevens, Kristien Van Dyck, Arthur Bergman, Bingming Yi, Michael Tanen

Clin Pharmacol Ther· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Localization of PPARdelta in murine central nervous system: expression in oligodendrocytes and neurons.
John W Woods, Michael Tanen, David J Figueroa, Chhabi Biswas, Emanuel Zycband

Brain Res· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.
Joel P Berger, Ann E Petro, Karen L Macnaul, Linda J Kelly, Bei B Zhang, Michael R Tanen

Mol Endocrinol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.
Terry P Combs, John A Wagner, Joel Berger, Tom Doebber, Wen-Jun Wang, Michael Tanen

Endocrinology· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis